Form 4 for IRD Opus Genetics, Inc.
Accepted 2025-09-11 00:00:00 ET · period of report 2025-09-02 · accession 0000905148-25-003320 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-11 | 2025-09-10 | IRD | Gagnon Robert E. | CFO | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
| D | 2025-09-11 | 2025-09-02 | IRD | Gagnon Robert E. | CFO | A - Grant | $0.00 | +250.0K | 250.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-10 | A | A | 200,000 | $0.00 | 200,000 | D | — | — | (F1) Represents a grant of restricted stock units which vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-09-02 | A | A | 250,000 | $0.00 | 250,000 | D | $1.23 · — to 2035-09-01 | 250,000 Common Stock | (F2) The option will vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service. |